Paxlovid (Eua) (Nirmatrelvir/Ritonavir) Patent Expiration, LOE Window & CMS Spending

Paxlovid (Eua) (Nirmatrelvir/Ritonavir) by Pfizer: FDA Orange Book core substance LOE 2041-08-05 (last listed 2041-10-31), 0 AB generics, $3.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN217188 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-08-05
Last Listed Patent or Exclusivity Date2041-10-31
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.0M
2024 Medicare Part D Spend$2.7M
2024 Medicaid Spend$247K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.